R&D channel feed

As­traZeneca and Am­gen qui­et­ly ad­mit teze­pelum­ab set­back as the Dupix­ent chal­lenger heads to FDA

4 years ago

Alzheimer's ad­comm mem­bers ques­tion FDA: How can you use amy­loid as the ba­sis for an ac­cel­er­at­ed ap­proval?

4 years ago

Glax­o­SmithK­line punts a key Ze­ju­la com­bo study in ovar­i­an can­cer with added set­backs on ICOS and RSV

4 years ago

NewAms­ter­dam Phar­ma res­ur­rects Am­gen's old CETP drug with plans to jump in­to PhI­II this year

4 years ago

One Ring to rule them all? Flag­ship’s big bet on dom­i­nat­ing gene ther­a­py 2.0 at­tracts a $117M megaround

4 years ago

In Cure­Vac's fail­ure, a pos­si­ble ver­dict on the past (and fu­ture) of mR­NA vac­cines

4 years ago
In Focus

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

4 years ago
Deals

Pan­el of neu­ro­science ex­perts lays out the com­pli­ca­tions with us­ing Bio­gen's new Alzheimer's drug

4 years ago
Pharma
FDA+

Take­da flesh­es out CNS pact with pep­tide drug­mak­er, set­ting aside $3.5B in fu­ture mile­stones

4 years ago
Deals

Re­gen­eron's lat­est ge­net­ics dis­cov­ery hooks As­traZeneca — now all-in on de­vel­op­ing small mol­e­cules for obe­si­ty

4 years ago

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

4 years ago

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

4 years ago
Manufacturing

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

4 years ago
In Focus

Let the games be­gin: No­vo Nordisk takes the gold in Cowen's 'R&D pen­tathlon'

4 years ago

Eye­ing quick ap­proval, Ab­b­Vie of­fers a close-up on their pres­by­opia drug da­ta

4 years ago

The clock is tick­ing for Iterum af­ter FDA hands down CRL for Pfiz­er castoff an­tibi­ot­ic

4 years ago
FDA+

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

4 years ago

Small, strug­gling biotech winds up with a 3X los­er as an­oth­er PhI­II of its lead drug col­laps­es

4 years ago

6 top drug­mak­ers of­fer per­spec­tives on FDA's new co­vari­ates in RCTs guid­ance

4 years ago
Pharma

Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

4 years ago
Cell/Gene Tx

New da­ta show Bio­Mar­in's trou­bled he­mo­phil­ia gene ther­a­py con­tin­ues to fade, open­ing room for ri­vals

4 years ago

'By no means are we de­terred': Seres' stock spi­rals af­ter PhII mi­cro­bio­me fail in ul­cer­a­tive col­i­tis

4 years ago

No­var­tis dis­cards one of its ‘wild card’ drugs af­ter it flops in key study. But it takes one more for the hand

4 years ago

FDA lev­els clin­i­cal hold on Ma­gen­ta's sec­ond lead drug, ask­ing for an ad­di­tion­al bioas­say be­fore it gets to hu­mans

4 years ago
First page Previous page 163164165166167168169 Next page Last page
A service from the Financial Times